Supplementary Online Content

Kharfan-Dabaja MA, Labopin M, Polge E, et al. Association of second allogeneic hematopoietic cell transplant vs donor lymphocyte infusion with overall survival in patients with acute myeloid leukemia relapse. *JAMA Oncol*. Published online July 12, 2018. doi:10.1001/jamaoncol.2018.2091

eTable 1. Patient, Disease and Treatment Related Characteristics at Time of Allo-HCT1 (All Population on Intent-to Receive First Intervention)

eTable 2. Causes of Non-Relapse Deaths (DLI vs. Allo-HCT2

eTable 3. Multivariate Analysis for NRM and OS (All Patients)

eTable 4. Multivariate Analysis for RI, LFS, NRM and OS (Only Patients in CR)

eTable 5. Patient-, Disease-, and Treatment-Related Characteristics of Patients Who Received Only Allo-HCT2 or DLI

eTable 6. Treatment Outcomes for Patients Who Received Only Allo-HCT2 or DLI

eTable 7. Causes of Non-Relapse Deaths (DLI vs. Allo-HCT2) for Patients Who Received Only Allo-HCT2 or DLI

eTable 8. Multivariate Analysis for NRM and OS (All Patients) Who Received Only Allo-HCT2 or DLI

eFigure 1. OS (Allo-HCT2 vs. DLI), Patients in CR at Time of Intervention

eFigure 2. LFS (Allo-HCT2 vs. DLI), Patients in CR at Time of Intervention

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable 1. Patient, Disease and Treatment Related Characteristics at Time of Allo-HCT1 (All Population on Intent-to Receive First Intervention)

Variables	DLI (n=281) DLI only=230 DLI+allo-HCT2=51	Allo-HCT2 (n=137) Allo-HCT2 only=135 Allo-HCT2+DLI=2	p-value
Median age (range), years, at intervention	48 (18-73) IQR=37-57	43 (18-67) IQR=32-52	0.001
Recipient gender Female Male	128 (46%) 153 (54%)	62 (45%) 75 (55%)	0.95
Donor gender Female Male Missing/unknown	88 (31%) 192 (69%) 1	42 (31%) 95 (69%) 0	0.87
Donor→recipient gender matching F→M Others Missing/unknown	44 (16%) 236 (84%) 1	26 (19%) 111 (81%)	0.40
AML <i>de novo</i> Secondary	245 (87%) 36 (13%)	114 (83%) 23 (17%)	0.27
Cytogenetic risk Good Intermediate Poor Unknown/failed	25 (9%) 153 (54%) 77 (27%) 26 (9%)	8 (6%) 88 (64%) 32 (23%) 9 (7%)	0.26

@ 2018 American Medical Association. All rights reserved. 2

Remission status at time of allo-HCT1			0.03
CR1	218 (78%)	119 (87%)	
CR2	56 (20%)	18 (13%)	
CR3	7 (2%)	0	
Median (range), year of allo-HCT1	2007 (1992-2014)	2006 (1996-2014)	0.03
Regimen used for allo-HCT1			0.02
MAC	154 (55%)	92 (67%)	
RIC	126 (45%)	45 (33%)	
Missing/unknown	1	0	
Donor source			0.08
MRD	149 (53%)	85 (62%)	
URD	132 (47%)*	52 (38%)**	
Cell source			0.28
BM	51 (18%)	31 (23%)	
PBSC	230 (82%)	106 (77%)	
In vivo T-cell			0.006
depletion			
Yes	158 (57%)^	57 (43%)^^	
No	120 (43%) 3	77 (57%)	
Missing/unknown	3	3	

Patient CMV serology Positive Negative Missing/unknown	181 (65%) 97 (35%) 3	74 (55%) 60 (45%) 3	0.053
Donor CMV serology Positive Negative Missing/unknown	131 (48%) 143 (52%) 7	72 (54%) 62 (46%) 3	0.26

Bold denotes significant difference

Abbreviations: DLI, donor lymphocyte infusion; allo-HCT2, second allogeneic hematopoietic cell transplant; IQR, interquartile range; F, female; M, male; CR1, first complete remission; CR2, second complete remission; CR3, third complete remission; allo-HCT1, first allogeneic hematopoietic cell transplant; MAC, myeloablative conditioning regimen; RIC, reduced intensity conditioning regimen; MRD, HLA-matched related donor; URD, unrelated donor; BM, bone marrow cells; PBSC, peripheral blood stem cells; CMV, cytomegalovirus

*HLA-matched unrelated: 8/8 (n=4), 10/10 (n=65); HLA-mismatched unrelated: 7/8 (n=3), 9/10 (n=30), 8/10 (n=3), <7/82 (n=2), ≤ 5/6 (n=12), unknown/missing (n=13)

** HLA-matched unrelated: 8/8 (n=2), 10/10 (n=29); HLA-mismatched unrelated: 9/10 (n=6), 8/10 (n=3), ≤ 5/6 (n=3),

unknown/missing (n=9)

^antithymocyte globulin (n=132), alemtuzumab (n=26)

^^ antithymocyte globulin (n=50), alemtuzumab (n=7)

Causes of non-relapse deaths	DLI (n=52)	Allo-HCT2 (n=50)
Infection	21	22
GVHD	17	18
Hepatic SOS/VOD	0	4
Hemorrhage	4	1
Cardiac	0	1
Idiopathic pulmonary syndrome	2	0
Secondary malignancies	3	1
Other transplant related	10*	4**

eTable 2. Causes Of Non-Relapse Deaths (DLI vs. Allo-HCT2)

Abbreviations: GVHD, graft-versus-host disease; SOS/VOD, sinusoidal obstructive syndrome/veno-occlusive disease *Euthanasia (n=1), terminal cachexia with secondary multiorgan failure (n=1), transplant-related but exact cause unknown (n=8)

** Transplant-related but exact cause unknown (n=4)

Variables	NRM (all pat	tients)	OS (all patients)	
	HR (95%Cl)	p-value	HR (95%CI)	p-value
Allo-HCT2 vs. DLI	4.06 (2.32-7.08)	<0.0001	1.23 (0.95-1.60)	0.12
Age at intervention (per 10 years)	1.20 (0.96-1.51)	0.11	1.05 (0.95-1.15)	0.36
Poor risk cytogenetics vs. others	1.33 (0.73-2.42)	0.35	1.42 (1.10-1.84)	0.008
Secondary vs. <i>de novo</i> AML	0.75 (0.34-1.63)	0.46	1.17 (0.85-1.61)	0.34
Year of allo-HCT1	1.01 (0.94-1.09)	0.78	0.99 (0.96-1.02)	0.48
CR1 at time of allo-HCT1	0.73 (0.37-1.42)	0.35	0.95 (0.70-1.28)	0.73
URD vs. MRD at allo-HCT1	1.00 (0.28-3.56)	1.0	0.80 (0.44-1.45)	0.46
RIC vs. MAC at allo-HCT1	0.94 (0.52-1.71)	0.84	1.25 (0.96-1.63)	0.09
Grade 2-4 vs. none aGVHD prior to DLI/allo-HCT2	2.18 (1.14-4.17)	0.02	1.62 (1.15-2.29)	0.006
cGVHD (all grades) vs. none prior to DLI/allo-HCT2	1.04 (0.59-1.83)	0.90	0.71 (0.53-0.95)	0.02
Time from allo-HCT1 to relapse (months)	0.99 (0.98-1.00)	0.15	0.99 (0.98-0.99)	0.0003
Time from relapse to DLI/allo-HCT2 (months)	0.98 (0.85-1.13)	0.81	0.97 (0.91-1.04)	0.42
Other donor vs. MRD	1.27 (0.37-4.37)	0.71	1.32 (0.74-2.36)	0.34
CR vs. no CR at DLI/allo-HCT2	0.91 (0.50-1.67)	0.76	0.55 (0.41-0.74)	<0.0001

eTable 3. Multivariate Analysis for NRM and OS (All Patients)

Bold denotes significant difference

Abbreviations: NRM, non-relapse mortality; OS, overall survival; allo-HCT2, second allogeneic hematopoietic cell transplant; DLI, donor lymphocyte infusion; allo-HCT1, first allogeneic hematopoietic cell transplant; CR1, first complete remission; MRD, HLA-matched related donor; URD, unrelated donor; MAC, myeloablative conditioning regimen; RIC, reduced intensity conditioning regimen; aGVHD, acute graft-versus-host disease; cGVHD, chronic GVHD

Variables	RI		LFS		NRM		OS	
	HR (95%CI)	p-value	HR (95%CI)	p- value	HR (95%CI)	p- value	HR (95%CI)	p- value
Allo-HCT2 vs. DLI	1.21 (0.63-2.31)	0.56	1.52 (0.88-2.63)	0.14	2.93 (0.96-8.88)	0.06	1.55 (0.89-2.71)	0.12
Age at intervention (per 10 years)	0.90 (0.73-1.12)	0.35	0.92 (0.77-1.11)	0.39	0.99 (0.66-1.46)	0.94	0.95 (0.77-1.16)	0.59
Year of allo-HCT1	1.01 (0.93-1.09)	0.80	1.04 (0.97-1.11)	0.25	1.12 (0.97-1.29)	0.12	1.05 (0.98-1.13)	0.18
Grade 2-4 vs. none aGVHD prior to DLI/allo-HCT2	1.36 (0.59-3.14)	0.47	1.82 (0.95-3.48)	0.07	3.75 (1.23-11.41)	0.02	2.42 (1.22-4.77)	0.01
cGVHD (all grades) vs. none prior to DLI/allo-HCT2	0.91 (0.46-1.80)	0.79	0.97 (0.55-1.70)	0.90	1.18 (0.42-3.36)	0.76	0.97 (0.53-1.77)	0.93
Time from allo-HCT1 to relapse (months)	1.00 (0.98-1.01)	0.56	1.00 (0.99-1.01)	0.85	1.01 (0.98-1.03)	0.71	1.00 (0.99-1.01)	0.98
Time from relapse to DLI/allo-HCT2 (months)	0.99 (0.86-1.13)	0.84	0.95 (0.84-1.07)	0.36	0.88 (0.69-1.11)	0.28	0.91 (0.80-1.03)	0.13
Status at intervention CR3 vs. CR2	1.67 (0.79-3.54)	0.18	1.62 (0.84-3.13)	0.15	1.38 (0.34-5.56)	0.65	1.23 (0.63-2.40)	0.55
Poor risk cytogenetics vs. others	1.10 (0.52-2.32)	0.81	1.42 (0.77-2.60)	0.26	2.40 (0.76-7.54)	0.13	1.64 (0.85-3.18)	0.14
Other donor vs. MRD	1.02 (0.54-1.91)	0.96	1.40 (0.83-2.36)	0.21	3.51 (1.26-9.80)	0.02	1.84 (1.07-3.17)	0.03

eTable 4. Multivariate Analysis for RI, LFS, NRM and OS (Only Patients in CR)

Bold denotes significant difference

Abbreviations: RI, relapse incidence; LFS, leukemia-free survival; NRM, non-relapse mortality; OS, overall survival; allo-HCT2, second allogeneic hematopoietic cell transplant; DLI, donor lymphocyte infusion; allo-HCT1, first allogeneic hematopoietic cell transplant; aGVHD, acute graft-versus-host disease; cGVHD, chronic GVHD; CR2, second complete remission; CR3, third complete remission; MRD, HLA-matched related donor

Variables	DLI (n=230)	Allo-HCT2 (n=135)	p-value
Median age (range), years, at intervention	50 (19-75) IQR=40-60	43 (18-67) IQR=32-52	<0.0001
Recipient gender Female Male	102 (44%) 128 (56%)	62 (46%) 73 (54%)	0.77
Donor gender Female Male Missing/unknown	74 (33%) 153 (67%) 3	51 (38%) 82 (62%) 2	0.12
Same original donor Yes No Missing/unknown	224 (100%) - 6*	72 (60%) 49 (41%) 14	<0.0001
Remission status at intervention CR2 CR3 Relapsed 1 Relapsed 2	33 (14%) 14 (6%) 143 (62%) 40 (17%)	46 (34%) 7 (5%) 71 (53%) 11 (8%)	<0.0001
Donor source MRD URD Haploidentical Missing/unknown	122 (54%) 105 (46%) 0 3	75 (56%) 58 (43%) 2 (1%) 0	0.16

eTable 5. Patient-, Disease-, and Treatment-Related Characteristics of Patients Who Received Only Allo-HCT2 or DLI

© 2018 American Medical Association. All rights reserved. 8

Cell source			0.42
BM	9 (4%)	6 (4%)	0.42
PBSC	217 (96%)	128 (95%)	
BM+PBSC	0	1 (1%)	
Missing/unknown	4	0	
wissing/unknown	T	0	
Median time (range)	193 (20-3872)	342 (30-4569)	0.005
from allo-HCT1 to	IQR=114-482	IQR=132-699	
relapse, days			
· · · · · · · · · · · · · · · · · · ·			
Median time from	32 (0-305)	68 (6-311)	<0.0001
allo-HCT1 relapse to	IQR=17-69	IQR=39-119	
intervention, days			
Grade 2-4 aGVHD			0.003
prior to intervention			
Yes			
No	18 (8%)	24 (18%)	
	· · ·		
Missing/unknown	212 (92%)	108 (82%)	
	· · ·		
cGVHD (any grade)	212 (92%)	108 (82%)	0.43
cGVHD (any grade) prior to intervention	212 (92%)	108 (82%)	0.43
cGVHD (any grade) prior to intervention Yes	212 (92%) 3	108 (82%) 3	0.43
cGVHD (any grade) prior to intervention Yes No	212 (92%) 3 46 (21%)	108 (82%) 3 32 (25%)	0.43
cGVHD (any grade) prior to intervention Yes	212 (92%) 3 46 (21%) 170 (79%)	108 (82%) 3	0.43
cGVHD (any grade) prior to intervention Yes No Missing/unknown	212 (92%) 3 46 (21%)	108 (82%) 3 32 (25%)	0.43
cGVHD (any grade) prior to intervention Yes No Missing/unknown	212 (92%) 3 46 (21%) 170 (79%)	108 (82%) 3 32 (25%)	0.43
CGVHD (any grade) prior to intervention Yes No Missing/unknown Cytotoxic therapy including	212 (92%) 3 46 (21%) 170 (79%)	108 (82%) 3 32 (25%)	0.43
CGVHD (any grade) prior to intervention Yes No Missing/unknown Cytotoxic therapy including hypomethylating	212 (92%) 3 46 (21%) 170 (79%)	108 (82%) 3 32 (25%)	0.43
CGVHD (any grade) prior to intervention Yes No Missing/unknown Cytotoxic therapy including hypomethylating agents prior to DLI	212 (92%) 3 46 (21%) 170 (79%) 14	108 (82%) 3 32 (25%)	-
CGVHD (any grade) prior to intervention Yes No Missing/unknown Cytotoxic therapy including hypomethylating agents prior to DLI Yes	212 (92%) 3 46 (21%) 170 (79%) 14 146 (66%)	108 (82%) 3 32 (25%)	-
CGVHD (any grade) prior to intervention Yes No Missing/unknown Cytotoxic therapy including hypomethylating agents prior to DLI Yes No	212 (92%) 3 46 (21%) 170 (79%) 14	108 (82%) 3 32 (25%)	-
CGVHD (any grade) prior to intervention Yes No Missing/unknown Cytotoxic therapy including hypomethylating agents prior to DLI Yes	212 (92%) 3 46 (21%) 170 (79%) 14 146 (66%)	108 (82%) 3 32 (25%)	-

Regimen used for allo-HCT2	-		-
MAC RIC		48 (37%) 83 (63%)	
Missing/unknown		4	

Bold denotes significant difference

Abbreviations: DLI, donor lymphocyte infusion; allo-HCT2, second allogeneic hematopoietic cell transplant; IQR, interquartile range; CR2, second complete remission; CR3, third complete remission; MRD, HLA-matched related donor; URD, unrelated donor; BM, bone marrow cells; PBSC, peripheral blood stem cells; allo-HCT1, first allogeneic hematopoietic cell transplant; aGVHD, acute graft-versus-host disease; cGVHD, chronic GVHD; MAC, myeloablative conditioning regimen; RIC, reduced intensity conditioning regimen

*Although information missing, these are presumably from same donor

Outcomes	DLI	Allo-HCT2	P-value
Response			<0.0001
CR (before and after) intervention CR (after) intervention No response Not available*	47 (20%) 62 (27%) 119 (52%) 2 (1%)	53 (39%) 52 (39%) 21 (16%) 9 (7%)	
OS (all patients) 2-year 5-year	24% (95%CI=19-30%) 14% (95%CI=9-19%)	26% (95%CI=18-33%) 18% (95%CI=11-25%)	0.51
NRM (all patients) 2-year 5-year	9% (95%Cl=6-13%) 10% (95%Cl=6-14%)	27% (95%Cl=20-35%) 29% (95%Cl=21-37%)	<0.0001
Grade 2-4 aGVHD after intervention (all patients) 2-year 5-year	22% (95%Cl=17-27%) 22% (95%Cl=17-27%)	37% (95%Cl=29-46%) 37% (95%Cl=29-46%)	0.003
Causes of death (all patients) Relapse Non-relapse	151 (77%) 44 (23%)	62 (55%) 51 (45%)	-

eTable 6. Treatment Outcomes for Patients Who Received Only Allo-HCT2 or DLI

Bold denotes significant difference

Abbreviations: DLI, donor lymphocyte infusion; allo-HCT2, second allogeneic hematopoietic cell transplant; CR, complete remission; OS, overall survival; NRM, non-relapse mortality; aGVHD, acute graft-versus-host disease

Causes of non-relapse	DLI	Allo-HCT2
deaths	(n=44)	(n=51)
Infection	14	22
GVHD	16	18
Hepatic SOS/VOD	0	4
Hemorrhage	2	1
Cardiac	0	1
Idiopathic pulmonary	1	0
syndrome		
Secondary malignancies	3	1
Other transplant related	8	4

eTable 7. Causes of Non-Relapse Deaths (DLI vs. Allo-HCT2) for Patients Who Received Only Allo-HCT2 or DLI


Abbreviations: GVHD, graft-versus-host disease; SOS/VOD, sinusoidal obstructive syndrome/veno-occlusive disease

Variables	NRM (all patients)		OS (all pati	ents)
-	HR (95%CI)	p-value	HR (95%CI)	p-value
Allo-HCT2 vs. DLI	4.06 (2.27-7.26)	<0.0001	1.11 (0.84-1.45)	0.47
Age at intervention (per 10 years)	1.18 (0.94-1.49)	0.15	1.05 (0.95-1.16)	0.39
Poor risk cytogenetics vs. others at time of allo-HCT1	1.53 (0.82-2.83)	0.18	1.43 (1.08-1.89)	0.01
Secondary vs. de novo AML	0.71 (0.31-1.60)	0.40	1.18 (0.85-1.65)	0.33
Year of allo-HCT1	1.01 (0.94-1.09)	0.76	0.98 (0.95-1.02)	0.30
CR1 at time of allo-HCT1	0.69 (0.35-1.38)	0.29	0.94 (0.68-1.29)	0.68
URD vs. MRD at allo-HCT1	0.77 (0.22-2.81)	0.70	0.68 (0.37-1.27)	0.22
RIC vs. MAC at allo-HCT1	0.86 (0.46-1.58)	0.62	1.13 (0.86-1.50)	0.38
Grade 2-4 vs. none aGVHD prior to DLI/allo-HCT2	2.21 (1.14-4.30)	0.02	1.57 (1.09-2.26)	0.02
cGVHD (all grades) vs. none prior to DLI/allo-HCT2	1.01 (0.56-1.82)	0.98	0.68 (0.50-0.93)	0.02
Time from allo-HCT1 to relapse (months)	0.99 (0.98-1.01)	0.25	0.98 (0.98-0.99)	<0.0001
Time from relapse to DLI/allo-HCT2 (months)	0.92 (0.78-1.08)	0.31	0.96 (0.90-1.03)	0.32
Other donor vs. MRD at DLI/allo- HCT2	1.60 (0.45-5.63)	0.47	1.53 (0.84-2.80)	0.17
CR vs. no CR at DLI/allo-HCT2	0.90 (0.48-1.69)	0.75	0.56 (0.42-0.76)	0.0002

eTable 8. Multivariate Analysis for NRM and OS (All Patients) Who Received Only Allo-HCT2 or DLI


Bold denotes significant difference

Abbreviations: NRM, non-relapse mortality; OS, overall survival; allo-HCT2, second allogeneic hematopoietic cell transplant; DLI, donor lymphocyte infusion; allo-HCT1, first allogeneic hematopoietic cell transplant; CR1, first complete remission; MRD, HLA-matched related donor; URD, unrelated donor; MAC, myeloablative conditioning regimen; RIC, reduced intensity conditioning regimen; aGVHD, acute graft-versus-host disease; cGVHD, chronic GVHD






© 2018 American Medical Association. All rights reserved. 14



eFigure 2. LFS (Allo-HCT2 vs. DLI), Patients in CR at Time of Intervention



number of at-risk patients

— DLI	51	22	17	8	8	7
– – - Allo-HCT2	53	25	10	9	8	7

© 2018 American Medical Association. All rights reserved. 15